KR102087918B1 - 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용 - Google Patents

융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용 Download PDF

Info

Publication number
KR102087918B1
KR102087918B1 KR1020177029920A KR20177029920A KR102087918B1 KR 102087918 B1 KR102087918 B1 KR 102087918B1 KR 1020177029920 A KR1020177029920 A KR 1020177029920A KR 20177029920 A KR20177029920 A KR 20177029920A KR 102087918 B1 KR102087918 B1 KR 102087918B1
Authority
KR
South Korea
Prior art keywords
group
compound
mmol
added
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177029920A
Other languages
English (en)
Korean (ko)
Other versions
KR20170123705A (ko
Inventor
주셩 쑤
농 장
칭루이 순
티안지 우
Original Assignee
상하이 잉리 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 잉리 파마슈티컬 컴퍼니 리미티드 filed Critical 상하이 잉리 파마슈티컬 컴퍼니 리미티드
Publication of KR20170123705A publication Critical patent/KR20170123705A/ko
Application granted granted Critical
Publication of KR102087918B1 publication Critical patent/KR102087918B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177029920A 2015-03-24 2016-02-01 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용 Active KR102087918B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510131828 2015-03-24
CN201510131828.5 2015-03-24
PCT/CN2016/073043 WO2016150255A1 (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用

Publications (2)

Publication Number Publication Date
KR20170123705A KR20170123705A (ko) 2017-11-08
KR102087918B1 true KR102087918B1 (ko) 2020-03-12

Family

ID=56977003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177029920A Active KR102087918B1 (ko) 2015-03-24 2016-02-01 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용

Country Status (14)

Country Link
US (2) US10100015B2 (enExample)
EP (1) EP3275867B1 (enExample)
JP (1) JP6449482B2 (enExample)
KR (1) KR102087918B1 (enExample)
CN (3) CN106008340B (enExample)
AU (1) AU2016236669B2 (enExample)
CA (1) CA2980484C (enExample)
IL (1) IL254098B (enExample)
MX (1) MX383376B (enExample)
NZ (1) NZ735044A (enExample)
RU (1) RU2683566C1 (enExample)
SG (1) SG11201706869XA (enExample)
TW (2) TWI666201B (enExample)
WO (1) WO2016150255A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106008340B (zh) 2015-03-24 2020-03-17 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CN109790155B (zh) * 2016-05-23 2022-02-18 东宝紫星(杭州)生物医药有限公司 噻吩化合物及其合成方法和其在医药上的应用
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108033909A (zh) * 2017-12-20 2018-05-15 北京六合宁远科技有限公司 一种6-甲基-4-溴-异喹啉的制备方法
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111303161B (zh) * 2020-04-14 2021-01-05 遵义医科大学珠海校区 嘧啶并氮杂环类化合物及其用途
CN111763218B (zh) * 2020-07-14 2021-05-28 山东大学 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用
WO2023131017A1 (zh) * 2022-01-04 2023-07-13 上海璎黎药业有限公司 一种稠环衍生物的晶型、其制备方法及其应用
CN116465985B (zh) * 2023-03-03 2024-12-10 连云港杰瑞药业有限公司 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
CN118955327A (zh) * 2024-06-26 2024-11-15 安徽大学 一种4-溴-1-萘甲腈的合成方法
CN118878551A (zh) * 2024-07-08 2024-11-01 安徽大学 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528967A (ja) * 2003-05-21 2006-12-28 ファイザー・プロダクツ・インク ＰＰＡＲ−αアクチベータとしてのテトラヒドロイソキノリン誘導体
WO2007089557A2 (en) * 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
WO2009137404A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130115190A1 (en) 2011-05-05 2013-05-09 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558655A (en) 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US4224330A (en) 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
AUPO282896A0 (en) 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
WO2001021598A1 (en) 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
DE602004008505T2 (de) * 2003-11-20 2008-05-21 Eli Lilly And Co., Indianapolis Modulatoren des vitamin-d-rezeptors
ATE418567T1 (de) * 2003-12-22 2009-01-15 Basell Polyolefine Gmbh Metallocenverbindungen
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
CA2645712A1 (en) 2006-03-16 2007-09-20 Astellas Pharma Inc. Triazole derivative or salt thereof
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
EP2427430B1 (en) * 2009-05-04 2014-09-10 The Royal Institution for the Advancement of Learning/McGill University 5-oxo-ete receptor antagonist compounds
TW201116281A (en) 2009-08-06 2011-05-16 Astellas Pharma Inc N atom containing ring acylguanidine derivatives
JP5709146B2 (ja) * 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク． フェニルチオ酢酸化合物、組成物、および、その使用方法
CA2815716C (en) 2010-10-27 2019-06-11 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
US8987473B2 (en) * 2011-01-28 2015-03-24 Sato Pharmaceutical Co., Ltd. Ring-fused compound
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
US9512119B2 (en) 2012-07-27 2016-12-06 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
CA2890685A1 (en) 2012-11-20 2014-05-30 F. Hoffmann-La Roche Ag Substituted 1,6-naphthyridines
MX2015015052A (es) * 2013-05-03 2016-02-11 Hoffmann La Roche Derivados de isoquinolina que estimulan la neurogenesis.
US20170050936A1 (en) 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN115925679A (zh) * 2014-12-24 2023-04-07 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
CN106008340B (zh) 2015-03-24 2020-03-17 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528967A (ja) * 2003-05-21 2006-12-28 ファイザー・プロダクツ・インク ＰＰＡＲ−αアクチベータとしてのテトラヒドロイソキノリン誘導体
WO2007089557A2 (en) * 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
WO2009137404A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130115190A1 (en) 2011-05-05 2013-05-09 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors

Also Published As

Publication number Publication date
EP3275867A1 (en) 2018-01-31
CN108299425A (zh) 2018-07-20
CA2980484C (en) 2019-11-26
CN106008340A (zh) 2016-10-12
TWI675026B (zh) 2019-10-21
NZ735044A (en) 2018-10-26
TWI666201B (zh) 2019-07-21
CN108516958A (zh) 2018-09-11
IL254098B (en) 2020-03-31
JP2018509451A (ja) 2018-04-05
SG11201706869XA (en) 2017-09-28
US10100016B2 (en) 2018-10-16
CN108299425B (zh) 2020-09-18
WO2016150255A1 (zh) 2016-09-29
US10100015B2 (en) 2018-10-16
MX2017012009A (es) 2018-06-06
AU2016236669A1 (en) 2017-09-21
TW201641491A (zh) 2016-12-01
AU2016236669B2 (en) 2018-11-08
KR20170123705A (ko) 2017-11-08
TW201808909A (zh) 2018-03-16
US20180072678A1 (en) 2018-03-15
US20180265476A1 (en) 2018-09-20
RU2683566C1 (ru) 2019-03-29
EP3275867A4 (en) 2018-01-31
HK1226055A1 (zh) 2017-09-22
EP3275867B1 (en) 2020-06-10
MX383376B (es) 2025-03-13
CN106008340B (zh) 2020-03-17
JP6449482B2 (ja) 2019-01-09
CA2980484A1 (en) 2016-09-29
CN108516958B (zh) 2020-07-17
IL254098A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
KR102087918B1 (ko) 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용
DE60316542T2 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
KR101720824B1 (ko) 카테콜 ｏ-메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
JP5297414B2 (ja) キサンチンオキシダーゼ阻害剤
KR20210089195A (ko) 비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
EP3733659A1 (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
CN109071498A (zh) 激酶抑制剂及其制备方法和用途
CA2930209A1 (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
WO1988009333A1 (fr) Compose a base de thieno(triazolo)diazepine et applications medicales de ce compose
JP2018513219A (ja) 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
JP2022504620A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
JP7530510B2 (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
JP2002020386A (ja) ピラゾロピリジン誘導体
PL165413B1 (pl) Sposób wytwarzania nowych pochodnych 6-arylo-5,6-dwuhydroimidazo [2,1-b] tiazolu PL PL
KR20150079677A (ko) 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
JP2018087173A (ja) 悪性脳腫瘍治療薬
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN118005630A (zh) 一类zak抑制剂、其制备方法及应用
CN118852164A (zh) Parp选择性抑制剂
AU2020372682A1 (en) Tricyclic compound and pharmaceutical use thereof
HK1226055B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN112552276A (zh) 苯并氧杂卓-5-酮类化合物及其制备方法和用途
HK40035588A (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
HK40035588B (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20171017

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171017

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190521

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200305

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200305

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240214

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250226

Start annual number: 6

End annual number: 6